Prevalence of Toxigenic in Hospitalized Patients in the Southwestern Province of Saudi Arabia: Confirmation Using the GeneXpert Analysis

Overview

Journal Libyan J Med

Specialty General Medicine

Date 2023 Dec 19

PMID 38112195

Authors

Nader Kameli

Vinod Kumar Basode

Ahmed Abdulhaq

Mohammed Uthman A Alamoudi

Khalid Amaash Mohammed Zain

Ahmad Hassn Ghzwani

Affiliations

Soon will be listed here.

Abstract

() is a leading cause of nosocomial infections in hospitalized patients worldwide. Stool samples were collected from 112 inpatients admitted to different hospitals and were screened for GDH + toxin A + B by immunoassay, and all positive samples by immunoassay were processed for molecular detection of using the GeneXpert assay. strains were detected in 12 (10.71%) out of 112 stool samples using the GDH + toxin A + B immunoassay method and toxigenic was confirmed in 5 stool samples using the GeneXpert molecular assay. strains were also detected in 7 (8.97%) out of 78 stool samples from intensive care unit patients, 3 (25%) out of 12 stool samples from internal medicine ward patients, 1 (11.11%) out of 9 stool samples from surgery ward patients, and 1 (10%) out of 10 stool samples from isolation ward patients using the GDH + toxin A + B immunoassay method and the toxigenic strain was confirmed in 1, 2, 1, and 1 stool samples, respectively, using the GeneXpert molecular assay. Toxigenic was confirmed in patients at 4 (51.14%) out of 7 hospitals. In the present study, we also analyzed the clinical information of patients with -positive stool samples who were receiving one or more antibiotics during hospitalization. The binary toxin gene (), the gene, and the strain polymerase chain reaction (PCR) ribotype 027 were not detected using the GeneXpert molecular assay among 12 positive samples by immunoassay. This study should aid in the prevention of unnecessary empiric therapy and increase the understanding of the toxigenic burden on the healthcare system in the southwestern province of Saudi Arabia.

Citing Articles

Advances in diagnostic assays for infection in adults.

Liu D, Chen S, Hu R, Qiu Y, Chen K, Xu Y Front Cell Infect Microbiol. 2024; 14:1492511.

PMID: 39720791 PMC: 11666450. DOI: 10.3389/fcimb.2024.1492511.

References

Obaid N, Alhifany A . infections in Saudi Arabia: Where are we standing?. Saudi Pharm J. 2020; 28(9):1118-1121. PMC: 7474162. DOI: 10.1016/j.jsps.2020.07.013. View

Riddle D, Dubberke E . Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009; 23(3):727-43. PMC: 2726831. DOI: 10.1016/j.idc.2009.04.011. View

Hawkey P, Marriott C, Liu W, Jian Z, Gao Q, Ling T . Molecular epidemiology of Clostridium difficile infection in a major chinese hospital: an underrecognized problem in Asia?. J Clin Microbiol. 2013; 51(10):3308-13. PMC: 3811633. DOI: 10.1128/JCM.00587-13. View

Lanis J, Heinlen L, James J, Ballard J . Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog. 2013; 9(8):e1003523. PMC: 3731247. DOI: 10.1371/journal.ppat.1003523. View

Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J . Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005; 366(9491):1079-84. DOI: 10.1016/S0140-6736(05)67420-X. View

Singh M, Vaishnavi C, Kochhar R, Mahmood S . Toxigenic isolates from clinically significant diarrhoea in patients from a tertiary care centre. Indian J Med Res. 2017; 145(6):840-846. PMC: 5674555. DOI: 10.4103/ijmr.IJMR_192_16. View

McDonald L, Gerding D, Johnson S, Bakken J, Carroll K, Coffin S . Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66(7):e1-e48. PMC: 6018983. DOI: 10.1093/cid/cix1085. View

Buddle J, Fagan R . Pathogenicity and virulence of . Virulence. 2022; 14(1):2150452. DOI: 10.1080/21505594.2022.2150452. View

Fatima R, Aziz M . The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview. Cureus. 2019; 11(1):e3977. PMC: 6440555. DOI: 10.7759/cureus.3977. View

10.

Stahlmann J, Schonberg M, Herrmann M, von Muller L . Detection of nosocomial Clostridium difficile infections with toxigenic strains despite negative toxin A and B testing on stool samples. Clin Microbiol Infect. 2014; 20(9):O590-2. DOI: 10.1111/1469-0691.12558. View

11.

Akerlund T, Persson I, Unemo M, Noren T, Svenungsson B, Wullt M . Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol. 2008; 46(4):1530-3. PMC: 2292905. DOI: 10.1128/JCM.01964-07. View

12.

Surawicz C, Brandt L, Binion D, Ananthakrishnan A, Curry S, Gilligan P . Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4):478-98. DOI: 10.1038/ajg.2013.4. View

13.

Alzouby S, Baig K, AlRabiah F, Shibl A, Al-Nakhli D, Senok A . Clostridioides difficile infection: Incidence and risk factors in a tertiary care facility in Riyadh, Saudi Arabia. J Infect Public Health. 2019; 13(7):1012-1017. DOI: 10.1016/j.jiph.2019.10.014. View

14.

Wiuff C, Banks A, Fitzpatrick F, Cottom L . The Need for European Surveillance of CDI. Adv Exp Med Biol. 2018; 1050:13-25. DOI: 10.1007/978-3-319-72799-8_2. View

15.

Al-Tawfiq J, Abed M . Clostridium difficile-associated disease among patients in Dhahran, Saudi Arabia. Travel Med Infect Dis. 2010; 8(6):373-6. DOI: 10.1016/j.tmaid.2010.10.003. View

16.

Couturier J, Davies K, Gateau C, Barbut F . Ribotypes and New Virulent Strains Across Europe. Adv Exp Med Biol. 2018; 1050:45-58. DOI: 10.1007/978-3-319-72799-8_4. View

17.

Martin J, Monaghan T, Wilcox M . Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016; 13(4):206-16. DOI: 10.1038/nrgastro.2016.25. View

18.

Predrag S, Branislava K, Miodrag S, Biljana M, Suzana T, Natasa M . Clinical importance and representation of toxigenic and non-toxigenic Clostridium difficile cultivated from stool samples of hospitalized patients. Braz J Microbiol. 2013; 43(1):215-23. PMC: 3768987. DOI: 10.1590/S1517-838220120001000023. View

19.

Cheng J, Xiao M, Kudinha T, Xu Z, Hou X, Sun L . The First Two Clostridium difficile Ribotype 027/ST1 Isolates Identified in Beijing, China-an Emerging Problem or a Neglected Threat?. Sci Rep. 2016; 6:18834. PMC: 4703979. DOI: 10.1038/srep18834. View

20.

Markovska R, Dimitrov G, Gergova R, Boyanova L . , a New "Superbug". Microorganisms. 2023; 11(4). PMC: 10140992. DOI: 10.3390/microorganisms11040845. View